INVO Fertility
INVO Fertility operates a network of U.S. fertility clinics and manufactures the FDA-cleared INVOcell intravaginal culture device, offering a more affordable alternative to traditional IVF for individuals and couples seeking fertility treatment.
- Company typePublic
- Founded2017
- HeadquartersSarasota, United States
- Headcount11–50
- GTM typeB2B and B2C
- OfferingServices
What INVO Fertility does
INVO Fertility, Inc. (NASDAQ: IVF) is a U.S.-based fertility care company that operates a network of wholly-owned fertility clinics and manufactures the proprietary INVOcell medical device. Headquartered in Sarasota, Florida, the company runs clinics in Wisconsin (Wisconsin Fertility Institute), Alabama (Innovative Fertility Specialists), Georgia (Bloom Fertility), and Indiana (Family Beginnings, acquired February 2026), with a fifth Alabama location added via the HRCFG LLC acquisition in June 2026. Its core technology is INVOcell, the first FDA-cleared intravaginal culture (IVC) device, which enables fertilization and early embryo development to occur inside the patient's body over a 3–5 day incubation period rather than in a traditional IVF laboratory incubator. A modified single-chamber design of the device is covered by U.S. Patent No. 12,544,204 B2, with IP protection running through 2040. The Wisconsin clinic has additionally adopted time-lapse embryo incubation technology, and INVO has integrated Heidi Health's AI-powered clinical documentation platform at that site.
INVO Fertility generates revenue through two primary streams: direct-to-consumer fertility treatment services (IVF, IUI, egg retrieval, embryo transfer, fertility preservation) delivered through its owned clinic network, and sales of the INVOcell device to third-party fertility providers. Treatment pricing is quote-based and varies by protocol, with the company positioning INVOcell as a cost-effective alternative to traditional IVF by reducing laboratory resource requirements. In March 2026, INVO's Wisconsin clinic joined the Progyny fertility benefits network, opening in-network access to employer-sponsored fertility benefit members and adding a third payer channel alongside direct-pay patients and traditional insurance. Management also markets INVOcell internationally through a partnership solicitation program. FY2025 revenue was $6.84M (+5% YoY) with a net loss of $5.3M, and Q1 2026 revenue reached $2.0M (+23% YoY) with a net loss of $5.5M from continuing operations.
The company trades publicly on NASDAQ under the ticker IVF and has executed significant capital structure actions, including a 1-for-5 reverse stock split in March 2026 and an increase in authorized shares from 6.25M to 250M to fund growth. A $4.0M private placement closed in December 2025, bringing cash to $4.9M and stockholders' equity to $15.0M by Q1 2026. INVO has faced Nasdaq compliance challenges stemming from late SEC filings and announced a restatement of its 2025 Q1–Q3 financial statements in June 2026; Nasdaq subsequently closed the non-compliance matter after the Form 10-Q was submitted. The senior leadership team is led by CEO Steve Shum and includes executives with prior experience at Cooper Surgical and other IVF-sector companies.
INVO Fertility firmographics
Firmographics- Name
- INVO Fertility
- Legal name
- INVO Fertility, Inc.
- Website
- https://invofertility.com
- Company type
- Public
- Founded year
- 2017
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- INVO Fertility operates a network of U.S. fertility clinics and manufactures the FDA-cleared INVOcell intravaginal culture device, offering a more affordable alternative to traditional IVF for individuals and couples seeking fertility treatment.
- Ownership category
- akta.pro rank
INVO Fertility industry classification
Industry- Product category
- Reproductive Healthcare / Fertility Treatment Services
- NAICS
- Ambulatory Health Care Services (621), Family Planning Centers (62141), Other Ambulatory Health Care Services (6219)
- SIC
- Services-Specialty Outpatient Facilities, Nec (8093), Services-Offices & Clinics Of Doctors Of Medicine (8011)
- akta.pro primary industry
- Fertility, Reproductive Endocrinology & IVF Centers (HLAFAJAD)
- akta.pro secondary industry
- Reproductive Endocrinology & Infertility (IVF/Fertility) (HLAKAJAC)
Keywords
Where INVO Fertility is headquartered
LocationHeadquarters
- HQ city
- Sarasota
- HQ country
- United States
- HQ region
- North America
Offices5 records
Markets served
INVO Fertility business model
Business model- GTM type
- B2B and B2C
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales, Supply Chain
Revenue model
- Fertility Clinic Services: Revenue generated from operating fertility clinics providing assisted reproductive technology services including IVF, IUI, and related treatments. Consolidated clinic revenue grew 5% year-over-year, with four operational clinics across the US as of Q1 2026.
- INVOcell Device Sales: Revenue from the sale of the proprietary INVOcell medical device used in fertility treatments. The device enables fertilization and early embryo development within the patient's body.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Pay-as-you-go | Fertility treatment services - pricing varies by treatment type and individual patient needs |
Go-to-market motion2 records
Distribution channels3 records
Marketing channels4 records
INVO Fertility product offering
Product offeringCore offering
INVO Fertility operates a growing network of fertility clinics across the United States that deliver assisted reproductive technology services (including IVF, IUI, and INVOcell-based treatments) directly to patients. The company also develops, manufactures, and sells the proprietary INVOcell medical device, the first FDA-cleared intravaginal culture device that enables fertilization and early embryo development to occur inside the patient's body as a lower-cost alternative to traditional IVF.
Product overview
INVO Fertility operates as a healthcare services company offering a unified portfolio of fertility clinic services powered by its proprietary INVOcell technology. The company operates a network of four fertility clinics across the United States (Wisconsin Fertility Institute, Innovative Fertility Specialists, Bloom Fertility, and Family Beginnings), providing comprehensive fertility treatments and reproductive services. The core differentiator is INVOcell, the FDA-cleared intravaginal culture device that enables fertilization and early embryo development to occur within the patient's body, offering a more natural and cost-effective alternative to traditional IVF. The company generates revenue through both fertility clinic services and the sale/commercialization of the INVOcell medical device.
Differentiator
Problem solved
Functional benefit
Brands
- INVOcell: FDA-cleared medical device for intravaginal culture (IVC) fertility treatment, allowing fertilization and early embryo development to occur within the patient's body
- Wisconsin Fertility Institute
- Innovative Fertility Specialists
- Bloom Fertility
- Family Beginnings
Products and services
- INVOcell The first FDA-cleared medical device designed for intravaginal culture (IVC), allowing fertilization and early embryo development to occur within the woman's body rather than in a traditional laboratory incubator. The device is inserted into the upper vaginal cavity for 3-5 days, after which a selected embryo is transferred to the uterus. Sold to fertility clinics and providers as a more cost-effective alternative to traditional IVF.
- Wisconsin Fertility Institute
Quantifiable outcome
- Over 5,000 babies delivered at Wisconsin Fertility Institute since 2007
- +3 more outcomes
Companies that use INVO Fertility
Customer profileNamed customers5 records
Segments2 records
Ideal customer profiles1 record
INVO Fertility technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration1 record
AI capability2 records
Feature4 records
INVO Fertility partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- ProgynycoreINVO's Wisconsin clinic joined the Progyny network, becoming in-network for Progyny members' fertility benefits. This expands the clinic's market reach and provides access to Progyny's employer-sponsored fertility benefit members.
Scale indicators8 records
Recent moves8 records
Expansion highlights6 records
INVO Fertility competitors and assessment
Company assessmentBroad incumbents
- CooperSurgical: CooperSurgical is a division of CooperCompanies and a dominant player in the global IVF medical device and fertility solutions market. It is directly comparable to INVO Fertility as both sell IVF-related medical devices and consumables to fertility clinics, and multiple INVO executives (Jensen, Mitrovic) previously worked there.
- Inception Fertility: Inception Fertility is a US fertility clinic platform operating brands such as The Prelude Network and MyEggBank. It is comparable to INVO as a multi-brand fertility clinic operator pursuing scale through acquisitions of regional practices across the United States.
- Boston IVF: Boston IVF is a long-established US fertility clinic network affiliated with major academic medical centers, providing comprehensive ART services. It is comparable to INVO as a multi-clinic fertility services provider targeting similar patient demographics.
- Prelude Fertility: Prelude Fertility is a US fertility clinic network formed via acquisition roll-up of regional fertility practices. It is comparable to INVO in pursuing a clinic-acquisition growth strategy across US geographies to build a national fertility services platform.
- Shady Grove Fertility: Shady Grove Fertility is a large, multi-state US fertility clinic network offering IVF, IUI, and related treatments. It is comparable to INVO as a US fertility clinic network competing for patients in overlapping regional markets.
- CCRM Fertility: CCRM Fertility operates one of the largest US networks of fertility clinics with in-house lab capabilities and a strong brand among patients. It is comparable to INVO as a multi-clinic fertility services operator with national scale, though much larger and more established.
Direct peers
- Genea Biomedx: Genea Biomedx develops and commercializes IVF lab devices and ART instruments such as time-lapse incubators and embryo culture systems. It is directly comparable to INVOcell as a competing provider of next-generation IVF devices addressing embryology workflow needs.
- Vitrolife: Vitrolife is a Swedish-listed global provider of media, consumables, and devices for assisted reproductive technology, including IVF lab equipment. It is directly comparable to INVO as a supplier of IVF laboratory technology and devices used by fertility clinics worldwide.
Others
- Progyny: Progyny is a US fertility benefits management company whose employer-sponsored members are steered to in-network clinics, including INVO Fertility's Wisconsin location. It is comparable as both a channel partner that drives INVO patient flow and an adjacent ecosystem participant in employer-sponsored fertility care.
Emerging players
- Kindbody: Kindbody is a venture-backed fertility and family-building clinic operator with employer-facing benefits partnerships. It is comparable to INVO as a fertility clinic network pursuing employer-sponsored benefits relationships (Progyny, etc.) and direct-to-consumer fertility services.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks7 records
Key highlights7 records
Customer concentration
INVO Fertility social profiles
Digital presenceINVO Fertility financial estimates
Financial estimateRevenue estimate
Valuation estimate
INVO Fertility leadership team
Management profileNumber of profiles
Profiles6 records
INVO Fertility subsidiaries and ownership
Company hierarchySubsidiaries5 records
INVO Fertility funding detail
Funding detailFunding overview
Funding rounds1 record
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
INVO Fertility M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about INVO Fertility
What does INVO Fertility do?
INVO Fertility operates a growing network of fertility clinics across the United States that deliver assisted reproductive technology services (including IVF, IUI, and INVOcell-based treatments) directly to patients. The company also develops, manufactures, and sells the proprietary INVOcell medical device, the first FDA-cleared intravaginal culture device that enables fertilization and early embryo development to occur inside the patient's body as a lower-cost alternative to traditional IVF.
Is INVO Fertility a public or private company?
INVO Fertility is a public company. It is classified as public and is currently operating.
When was INVO Fertility founded?
INVO Fertility was founded in 2017. It employs 11 to 50 people.
Where is INVO Fertility based?
INVO Fertility is headquartered in Sarasota, United States, in the North America region.
How does INVO Fertility make money?
Two revenue lines are on record. Fertility Clinic Services are the primary driver. The others are INVOcell Device Sales.
Who are INVO Fertility's main competitors?
Broad incumbents on record are CooperSurgical, Inception Fertility, Boston IVF, Prelude Fertility, Shady Grove Fertility and CCRM Fertility. Direct peers are Genea Biomedx and Vitrolife. Progyny is listed as an others. Kindbody is listed as an emerging player.
Does INVO Fertility have an API?
No public API is recorded for INVO Fertility.
What industry is INVO Fertility in?
INVO Fertility's product category is Reproductive Healthcare / Fertility Treatment Services. Its primary akta.pro industry code is HLAFAJAD, Fertility, Reproductive Endocrinology & IVF Centers, with a secondary code of HLAKAJAC, Reproductive Endocrinology & Infertility (IVF/Fertility). Its NAICS code is 621 and its SIC code is 8093.